Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report
As one of the most common gastrointestinal tumors, Gastric Cancer (GC) poses a serious threat to human health due to its high morbidity and mortality. The current treatment strategy is a comprehensive treatment program mainly based on surgery, especially for advanced GC patients. The emergence of im...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1560450/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850186781453975552 |
|---|---|
| author | Xiaoke Wang Xiaoke Wang Yuanhui Gu Lin Yi Tao Wu Tao Wu Ling Wang Jiao Tian Yuyuan Lu Penghui Jin Xin Yang Yan Yang |
| author_facet | Xiaoke Wang Xiaoke Wang Yuanhui Gu Lin Yi Tao Wu Tao Wu Ling Wang Jiao Tian Yuyuan Lu Penghui Jin Xin Yang Yan Yang |
| author_sort | Xiaoke Wang |
| collection | DOAJ |
| description | As one of the most common gastrointestinal tumors, Gastric Cancer (GC) poses a serious threat to human health due to its high morbidity and mortality. The current treatment strategy is a comprehensive treatment program mainly based on surgery, especially for advanced GC patients. The emergence of immune checkpoint inhibitors has completely changed this status quo, and the synergistic effect of neoadjuvant immunotherapy combined with chemotherapy has significantly improved the resection and radical rate and overall survival of patients with advanced local GC. We present a case of locally advanced GC (cT4N0Mx) with microsatellite instability high (MSI-H) and PD-L1 Combined Positive Score (CPS)=2. The patient received neoadjuvant therapy with Sintilimab combined with FOLFOX (folinic acid (leucovorin), 5-fluorouracil (5-FU), and oxaliplatin), and significantly reduced tumor volume after 3 cycles of treatment. Then she underwent subtotal gastrectomy with gastrojejunostomy and D2 lymph node dissection. The postoperative pathological results showed that no cancerous tissue remained in the tumor tissue, and pathologic complete response (pCR) was achieved. The first cycle of adjuvant therapy with the same protocol was received after surgery. During adjuvant therapy, patients mainly experienced side effects such as dyspepsia, nausea and mild myelosuppression. Therefore, immunotherapy with Sintilimab combined with FOLFOX chemotherapy has the potential to be an effective treatment option for patients with resectable locally advanced MSI-H GC. |
| format | Article |
| id | doaj-art-9cdbd15f90944b8b9ec5010e7a5d0d93 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-9cdbd15f90944b8b9ec5010e7a5d0d932025-08-20T02:16:17ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-05-011510.3389/fonc.2025.15604501560450Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case reportXiaoke Wang0Xiaoke Wang1Yuanhui Gu2Lin Yi3Tao Wu4Tao Wu5Ling Wang6Jiao Tian7Yuyuan Lu8Penghui Jin9Xin Yang10Yan Yang11Department of General Surgery, Gansu Provincial Hospital, Lanzhou, Gansu, ChinaFirst School of Clinical Medical, Gansu University of Chinese Medicine, Lanzhou, Gansu, ChinaDepartment of General Surgery, Gansu Provincial Hospital, Lanzhou, Gansu, ChinaSchool of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, ChinaDepartment of General Surgery, Gansu Provincial Hospital, Lanzhou, Gansu, ChinaSchool of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, ChinaPathology Department, Gansu Provincial Hospital, Lanzhou, Gansu, ChinaSchool of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, ChinaSchool of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, ChinaFirst School of Clinical Medical, Gansu University of Chinese Medicine, Lanzhou, Gansu, ChinaFirst School of Clinical Medical, Gansu University of Chinese Medicine, Lanzhou, Gansu, ChinaPharmacy Department, Gansu Provincial Hospital, Lanzhou, Gansu, ChinaAs one of the most common gastrointestinal tumors, Gastric Cancer (GC) poses a serious threat to human health due to its high morbidity and mortality. The current treatment strategy is a comprehensive treatment program mainly based on surgery, especially for advanced GC patients. The emergence of immune checkpoint inhibitors has completely changed this status quo, and the synergistic effect of neoadjuvant immunotherapy combined with chemotherapy has significantly improved the resection and radical rate and overall survival of patients with advanced local GC. We present a case of locally advanced GC (cT4N0Mx) with microsatellite instability high (MSI-H) and PD-L1 Combined Positive Score (CPS)=2. The patient received neoadjuvant therapy with Sintilimab combined with FOLFOX (folinic acid (leucovorin), 5-fluorouracil (5-FU), and oxaliplatin), and significantly reduced tumor volume after 3 cycles of treatment. Then she underwent subtotal gastrectomy with gastrojejunostomy and D2 lymph node dissection. The postoperative pathological results showed that no cancerous tissue remained in the tumor tissue, and pathologic complete response (pCR) was achieved. The first cycle of adjuvant therapy with the same protocol was received after surgery. During adjuvant therapy, patients mainly experienced side effects such as dyspepsia, nausea and mild myelosuppression. Therefore, immunotherapy with Sintilimab combined with FOLFOX chemotherapy has the potential to be an effective treatment option for patients with resectable locally advanced MSI-H GC.https://www.frontiersin.org/articles/10.3389/fonc.2025.1560450/fulladvanced gastric cancerMSI-HPCRimmunotherapycase report |
| spellingShingle | Xiaoke Wang Xiaoke Wang Yuanhui Gu Lin Yi Tao Wu Tao Wu Ling Wang Jiao Tian Yuyuan Lu Penghui Jin Xin Yang Yan Yang Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report Frontiers in Oncology advanced gastric cancer MSI-H PCR immunotherapy case report |
| title | Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report |
| title_full | Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report |
| title_fullStr | Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report |
| title_full_unstemmed | Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report |
| title_short | Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report |
| title_sort | pathologic complete response after sintilimab combined with folfox therapy in msi h type patients with locally advanced gc a case report |
| topic | advanced gastric cancer MSI-H PCR immunotherapy case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1560450/full |
| work_keys_str_mv | AT xiaokewang pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport AT xiaokewang pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport AT yuanhuigu pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport AT linyi pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport AT taowu pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport AT taowu pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport AT lingwang pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport AT jiaotian pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport AT yuyuanlu pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport AT penghuijin pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport AT xinyang pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport AT yanyang pathologiccompleteresponseaftersintilimabcombinedwithfolfoxtherapyinmsihtypepatientswithlocallyadvancedgcacasereport |